Tag:

lovenox

Latest Headlines

Latest Headlines

Momenta pleads for Supreme Court review in Lovenox generic case

Momenta Pharmaceuticals really wants the U.S. Supreme Court to weigh its argument against Amphastar's rival version of generic Lovenox. But Amphastar is equally eager to keep the Supreme Court out of the case. 

Sanofi, Coca-Cola team up on 'Beautific' drinks

Sanofi ($SNY) and Coca-Cola. Odd couple or match made in commercial heaven? The two companies are engaging in a pilot project to find out. They're collaborating on a line of drinks, called Beautific Oenobiol, aiming to capture health-conscious consumers with claims about improved skin, stronger hair and increased vitality, The Wall Street Journal reports.

Watson, Amphastar launch Lovenox copy on court ruling

Momenta Pharmaceuticals ($MNTA) has lost its exclusive hold on the generic Lovenox market--at least temporarily. Amphastar, which has been developing its own version of the Sanofi ($SNY)

Sanofi spikes authorized Lovenox generic

It's official: Sanofi ($SNY) has discontinued its authorized generic version of the Lovenox blood thinner. Apparently, the company thinks it can make more money selling the branded med only, since

Eliquis fails to beat Lovenox at clot-fighting after surgery

In a study that could give versions of Sanofi's Lovenox a boost, the new Bristol-Myers Squibb ($BMY) and Pfizer ($PFE) anti-coagulant Eliquis failed to prove superior to the older drug in preventing

Judge blocks Amphastar's Lovenox copy

It looks as if Momenta Pharmaceuticals ($MNTA) will keep its share of the market for copycat Lovenox. The U.S.-based drugmaker and its partner Sandoz won an injunction against two potential rivals

Amphastar's Lovenox copy likely to shake market

Amphastar Pharmaceuticals finally has the FDA's blessing. After a protracted battle marked by lawsuits against the agency and conflicts of interest allegations, the company got U.S. regulatory

Senate report faults Sanofi contributions

The Senate Finance Committee is raising questions about Sanofi's multimillion-dollar contributions to two medical groups and a thrombosis researcher. The three of them all wrote letters to the FDA,

Teva appears close to Lovenox copy

Teva Pharmaceutical Industries is breathing down Momenta's neck. The Israeli generics maker is apparently close to getting FDA approval for its knockoff of the blood thinner Lovenox, and the prospect

Momenta sues to block rival Lovenox copycat

There's a new fight over generic Lovenox, and it doesn't involve the company that actually makes the branded version. Momenta Pharmaceuticals ($MNTA) and its partner Sandoz, which recently won FDA